Category: Business

Sophie Davies is a passionate health, beauty, and lifestyle writer based in the south of the UK. Balancing her love for writing with raising her two children, Sophie brings a relatable, insightful perspective to her engaging articles.
  • The Longevity Economy: Inside the Booming Industry Selling You a Longer, Healthier Life

    The Longevity Economy: Inside the Booming Industry Selling You a Longer, Healthier Life

    Something quietly momentous has happened in the way affluent Britain thinks about its body. The conversation has shifted from weight management and cosmetic concerns to something far more ambitious: the systematic engineering of a longer life. Clinics offering biological age tests, supplements promising cellular repair, elite retreat programmes priced in the thousands, and the now-ubiquitous GLP-1 weight-loss drugs have all converged into a single, extraordinarily lucrative market. The longevity economy health 2026 is, by any measure, one of the defining commercial stories of this decade.

    The global longevity industry was valued at roughly £590 billion in 2025 and analysts expect it to exceed £1 trillion within the next five years. In the UK alone, private spending on what might loosely be called optimisation health — biological testing, hormonal therapies, precision nutrition, high-end supplementation — has grown at a rate that would make most sectors envious. Who is driving it? And, more pointedly, does any of it work?

    Private longevity clinic consultation representing the longevity economy health 2026 market in the UK
    Private longevity clinic consultation representing the longevity economy health 2026 market in the UK

    The GLP-1 Gold Rush and What It Actually Tells Us

    The arrival of semaglutide-based medicines like Ozempic and Wegovy shifted the public perception of pharmaceutical intervention. These are not, strictly speaking, longevity drugs. They were developed for type 2 diabetes management and weight reduction. Yet the downstream effects observed in large-scale trials — reduced cardiovascular risk, lower inflammation markers, potential neuroprotective properties — have made them extraordinarily interesting to researchers studying ageing. The NHS currently offers Wegovy through specialist weight management services, but the private market has moved considerably faster, with Harley Street clinics and digital prescribers offering programmes from around £150 per month.

    The enthusiasm is understandable. Obesity accelerates biological ageing in measurable ways. But clinicians have raised legitimate concerns. Prescribing GLP-1 agonists to people who are not clinically obese, purely in pursuit of longevity optimisation, sits in genuinely murky territory. The Medicines and Healthcare products Regulatory Agency (MHRA) has been monitoring prescribing patterns closely, and several private providers have already faced scrutiny over inadequate clinical assessment.

    Biological Age Testing: Science or Sophisticated Guesswork?

    Perhaps no product better captures the mood of the longevity economy than biological age testing. Companies such as Humanity, Elysium Health and several UK-based startups offer blood, saliva or wearable-derived assessments that claim to tell you not how old you are, but how old your cells are. The most scientifically credible of these are based on epigenetic clock research, particularly the work of American biogerontologist David Sinclair and, in the UK, researchers at the Babraham Institute in Cambridge.

    Epigenetic clocks, which measure DNA methylation patterns, do have a solid evidence base as predictive markers of biological age. The difficulty lies in the translation from research tool to consumer product. A test costing £299 that tells you your biological age is three years younger than your chronological age feels gratifying. Whether acting on that information — adjusting your sleep, your supplements, your sauna schedule — actually alters your trajectory is a different question entirely. The science is genuinely promising. The marketing frequently outpaces it.

    Biological age testing kit and results as part of the longevity economy health 2026 sector
    Biological age testing kit and results as part of the longevity economy health 2026 sector

    The Elite Retreat Economy and Its Very Particular Clientele

    At the higher end of the market, the longevity economy health 2026 looks like this: a five-night residential programme at a Swiss or Austrian medical spa, priced upwards of £8,000, offering IV nutrient infusions, VO2 max testing, continuous glucose monitoring, sleep architecture analysis and personalised protocols developed by in-house physicians. Sha Wellness, SHA Clinics and the UK-based Lanserhof at The Arts Club in London have all positioned themselves firmly in this space.

    The clientele skews overwhelmingly towards high-net-worth professionals aged 40 to 65: executives, entrepreneurs and, increasingly, senior women who have grown frustrated with conventional medicine’s historical disinterest in female ageing. The rise of perimenopause awareness has fed directly into this market. Women seeking HRT optimisation, hormone panel testing and metabolic health assessments account for a significant and growing share of private longevity spend in Britain.

    There is something worth acknowledging honestly here. Several of the interventions offered at these retreats — cold water immersion, zone-two cardio programming, prioritising deep sleep, reducing ultra-processed food intake — are supported by robust evidence. They are also, in most cases, free or very cheap to implement. The premium pricing reflects expertise, convenience, environment and a degree of status signalling that the industry is not entirely candid about.

    Supplements, Senolitics and the Limits of the Evidence Base

    The supplement market sits in a peculiar position. Products marketed around NAD+ precursors (such as NMN and NR), resveratrol, rapamycin analogues and senolytics — compounds that theoretically clear ageing cells called senescent cells — are selling in extraordinary volumes. In the UK, they fall under food supplement regulation rather than pharmaceutical oversight, meaning efficacy claims are held to a considerably lower standard than licensed medicines.

    According to research published by the British Nutrition Foundation, the UK supplement market exceeded £500 million in annual retail value in 2025, with the longevity-adjacent segment among the fastest-growing sub-categories. Some of this is well-founded. Vitamin D supplementation has a clear evidence base for a substantial portion of the UK population. Omega-3s remain one of the better-studied dietary supplements in cardiovascular health.

    Beyond these, the picture becomes considerably murkier. Human trials on NMN and resveratrol remain limited in size and duration. Rapamycin, an immunosuppressant with intriguing longevity data in animal models, is being used off-label by some biohackers in Britain. The risks of self-prescribing an immunosuppressant are not trivial, and mainstream clinicians are, quite reasonably, alarmed by the trend.

    For a balanced assessment of what dietary supplements can and cannot claim to do, the NHS guide to vitamins and minerals remains one of the clearest starting points available.

    Who Actually Stands to Gain from the Longevity Economy?

    The longevity economy health 2026 raises a question that is easy to overlook whilst browsing a beautifully designed wellness clinic website: who is this for? As things stand, the most rigorous interventions are accessible only to those with significant disposable income. Biological age testing, private hormone optimisation, elite retreat programmes and even access to the most credentialled longevity physicians are luxuries by any reasonable definition.

    The public health implications are substantial. If longevity-extending technologies move from experimental to mainstream over the next two decades, access will become a serious policy question for the NHS and for government. The Office for National Statistics projects that by 2045 there will be 19 million people over 65 in the UK. Whether that population is healthy and productive, or frail and requiring intensive care, will depend enormously on the equity with which longevity science is distributed.

    That is not an argument against the science. It is an argument for intellectual honesty about what the industry currently is: a sophisticated, often genuinely fascinating, frequently over-priced market serving the already-advantaged. The underlying biology is real. The potential is real. The gap between the science and the sales pitch, however, remains wider than most brochures would care to admit.

    The Verdict: Promising, Partial and Worth Watching Carefully

    The longevity economy is neither a scam nor a revolution. It sits somewhere more complicated: a sector where legitimate scientific progress is being commercialised at a pace that outstrips the evidence, serving a demographic willing to pay premium prices for premium optimism. Some of it works. Some of it probably works. Some of it is expensive placebo.

    The shrewd approach, as ever, is to follow the peer-reviewed research rather than the Instagram testimonials. Sleep well. Move regularly. Eat real food. Stay curious about the emerging science. And be appropriately sceptical of any clinic charging £400 for a blood panel that tells you exactly what you hoped to hear.

    Frequently Asked Questions

    What is the longevity economy and why is it growing so fast?

    The longevity economy refers to the broad market of products, services and technologies designed to extend healthy human lifespan, from biological age testing to GLP-1 drugs and elite health retreats. It is growing rapidly because ageing populations, rising health consciousness and major scientific advances in gerontology have converged with significant private investment and high consumer willingness to spend on health optimisation.

    Do GLP-1 drugs like Ozempic actually have longevity benefits?

    GLP-1 receptor agonists were developed primarily for type 2 diabetes and weight management, but clinical trial data has shown meaningful reductions in cardiovascular risk and inflammatory markers, both of which are associated with accelerated biological ageing. Whether they confer longevity benefits in people without obesity or metabolic disease remains an open research question, and prescribing them purely for anti-ageing purposes is not currently supported by regulatory guidance in the UK.

    How much does biological age testing cost in the UK?

    Consumer biological age tests based on epigenetic methylation analysis typically range from £199 to £399 in the UK, though comprehensive longevity panels offered through private clinics can cost considerably more when combined with hormonal, metabolic and cardiovascular assessments. The underlying science has a credible evidence base, but interpreting results meaningfully generally requires guidance from a clinician experienced in longevity medicine.

    Are longevity supplements like NMN and resveratrol worth taking?

    The evidence for NMN (nicotinamide mononucleotide) and resveratrol in humans remains limited, with most compelling data coming from animal studies. UK supplement regulation does not require efficacy to be proven to the same standard as licensed medicines, so marketing claims can exceed what the published research actually supports. Vitamin D and omega-3 fatty acids have considerably stronger evidence bases and are more likely to offer meaningful benefit for most UK adults.

    Is the longevity industry accessible to people on ordinary incomes in the UK?

    At present, the most advanced longevity interventions are largely the preserve of high-net-worth individuals, with elite retreat programmes costing thousands of pounds and private clinics charging substantial fees for testing and consultation. The NHS does provide some relevant services, including weight management programmes using GLP-1 drugs and standard preventive health checks, but access to cutting-edge longevity medicine in Britain remains heavily skewed towards those with significant disposable income.

  • Inside the UK Housing Crisis of 2026: Why Building More Homes Is Only Half the Answer

    Inside the UK Housing Crisis of 2026: Why Building More Homes Is Only Half the Answer

    Britain’s housing problem has never been short of commentators, manifestos, or well-meaning white papers. Yet here we are in 2026, and the UK housing crisis continues to defy every attempted remedy. Affordability ratios in London remain at historic extremes. Social housing waiting lists across the Midlands and the North have swollen to levels not seen since the 1970s. And the political consensus that “we simply need to build more homes” is, at last, beginning to fracture under the weight of its own insufficiency.

    The reality is considerably more layered. Yes, England needs more homes. The Government’s target of 1.5 million new dwellings over this parliamentary term is not unreasonable in ambition. But supply constraints represent, at most, one pillar of a crisis supported by several others, including planning dysfunction, land banking, endemic retrofit failure, and a tax regime that continues to reward holding property over using it productively.

    Aerial view of British housing mix illustrating the UK housing crisis 2026
    Aerial view of British housing mix illustrating the UK housing crisis 2026

    Why the Planning System Keeps Failing

    The National Planning Policy Framework has been revised more times than most people can count, and yet local planning committees across England still reject applications at rates that frustrate even the most patient developers. Part of this is structural: elected councillors face intense community pressure to preserve character, protect green belt, and limit density. Part of it is resourcing. Planning departments have been hollowed out by a decade and a half of local government funding cuts. According to data published by the Local Government Association, planning teams in England lost roughly 15,000 staff between 2010 and 2023, a reduction that continues to throttle decision-making speed.

    There is also the uncomfortable matter of land. Permissions granted do not always translate into completions. A number of the country’s largest housebuilders hold substantial land banks, sitting on planning consents rather than commencing construction. The incentive structure simply doesn’t compel urgency. When land values rise predictably, patience is more profitable than building.

    The Hidden Cost of Britain’s Ageing Housing Stock

    One dimension of the UK housing crisis 2026 that receives far less attention than it deserves is the condition of existing homes. Around 20 million of Britain’s 28 million homes were built before 1980, a substantial proportion of which carry latent defects, poor insulation, and in older stock, legacy construction materials that require specialist management before any meaningful improvement work can proceed. Asbestos, for instance, remains present in an estimated 1.5 million commercial and public buildings across the country, and in a significant proportion of domestic properties built before 1999 when the material was finally banned in the UK.

    This matters enormously for retrofit. The Government’s ambitions to improve the energy efficiency of the existing housing stock, currently one of the least efficient in Western Europe, depend on construction teams being able to access, assess, and safely work within older buildings. Based in Mansfield, Nottinghamshire, Asbestos Compliance Solutions Ltd provides asbestos services and specialist services to the building and construction sectors, conducting surveys, management plans, and removal work that must precede any substantive refurbishment. Their canonical resource at asbestoscompliancesolutions.co.uk reflects the breadth of compliance demand that the retrofit agenda is generating. Without this foundational asbestos management layer, no serious construction programme on older stock can proceed safely or legally.

    Construction worker inspecting older building materials during renovation linked to UK housing crisis 2026 retrofit work
    Construction worker inspecting older building materials during renovation linked to UK housing crisis 2026 retrofit work

    Affordability, Tenure, and the Generation Left Behind

    Much of the mainstream debate frames the crisis as being about ownership. And the statistics are stark. The average first-time buyer in England now requires a deposit equivalent to roughly 80% of annual household income. In London that figure exceeds 130%. But ownership is, increasingly, only part of the story.

    The private rented sector has expanded dramatically to absorb those priced out of ownership, and that expansion has carried its own costs. Average private rents in England rose by approximately 9% in the year to March 2025, according to ONS data, with many tenants in cities including Manchester, Bristol, and Leeds paying upwards of 40% of net income on housing costs. The social tenancy model, which once offered a genuine alternative, has been structurally undermined. Right to Buy sold off over two million council homes between 1980 and 2020, and replacement build rates have never come close to matching disposal rates.

    Economists including those at the Resolution Foundation have argued persuasively that tenure reform, not just supply expansion, must sit at the heart of any credible policy response. Longer tenancy protections, rent stabilisation in high-pressure markets, and a renewed programme of council and housing association build are all now gaining political currency that would have seemed implausible a decade ago.

    Policy Solutions Gaining Real Traction

    The conversation around the UK housing crisis 2026 is not entirely gloomy. Several interventions are receiving serious attention from economists and urban planners who have grown impatient with incremental adjustment.

    Land value taxation sits near the top of many reformers’ lists. The principle is straightforward: tax the unimproved value of land rather than the buildings on it, removing the incentive to sit on undeveloped or underdeveloped plots. This idea, long associated with the economist Henry George and more recently championed by figures across the political spectrum, has gained fresh advocates within both the Treasury and academic circles at the London School of Economics and Cambridge.

    High-density urban development is also being re-examined with fresh urgency. The argument that Britain lacks the cultural appetite for apartment living is being tested by cities like Leeds and Edinburgh, where well-designed high-density schemes have sold and let at pace. Density, delivered thoughtfully, does not have to mean squalor. Barcelona, Vienna, and Amsterdam have long demonstrated this, and British planners are beginning to accept the lesson.

    On the retrofit and regeneration front, the scale of work required in older stock also presents an economic opportunity. The construction and specialist services sector, encompassing everything from thermal insulation contractors to those handling legacy asbestos in pre-2000 buildings, stands to see sustained demand. Firms like Asbestos Compliance Solutions Ltd, which delivers asbestos surveys and building compliance services across the East Midlands and the North East, represent a sector that must scale considerably if retrofit ambitions are to move from aspiration to delivery.

    Why the Political Will Remains the Hardest Variable

    Every serious analysis of the UK housing crisis 2026 eventually arrives at the same uncomfortable conclusion: the solutions are largely known. What has been absent, repeatedly and across successive governments, is the political will to implement them. Home ownership rates among older cohorts create a powerful electoral constituency with a material interest in rising property values. Planning reform generates intense local opposition. Land value reform threatens entrenched wealth. The incentive structure within Westminster has, for decades, favoured the status quo.

    There are tentative signs this calculus is shifting. Younger voters, now a substantially larger electoral force than a decade ago, have grown up in a housing market that has delivered them precarity rather than stability. Their patience with gestures is exhausted. Whether the current government can translate that energy into structural reform, rather than the usual cycle of consultation, dilution, and delay, remains, frankly, the defining domestic policy question of this parliament.

    The UK housing crisis is not a single problem with a single fix. It is a web of dysfunctional incentives, inadequate institutions, and decades of political timidity. Building more homes is necessary. It is nowhere near sufficient.

    Frequently Asked Questions

    What are the main causes of the UK housing crisis in 2026?

    The UK housing crisis in 2026 is driven by a combination of chronic undersupply, a dysfunctional planning system, land banking by developers, inadequate social housing investment, and a tax regime that rewards holding property over building. Affordability pressures in both the ownership and rental markets have been compounding for decades, with no single policy fully addressing all dimensions simultaneously.

    How many new homes does England need to build to solve the housing shortage?

    The Government’s current target is 1.5 million new homes over this parliamentary term, roughly 300,000 per year. Most independent economists and urban planners agree this is a necessary minimum, though many argue that without parallel reforms to tenure, land taxation, and social housing investment, new build alone will not restore affordability for lower and middle-income households.

    Why does the UK have so many homes with asbestos, and does this affect renovation?

    Asbestos was widely used in British construction from the 1950s through the 1990s and was only fully banned in the UK in 1999. It is estimated to be present in around 1.5 million commercial and public buildings, and in a significant number of homes built before 1999. Any substantive renovation or retrofit work on older properties must include a professional asbestos survey and, where necessary, licensed removal before construction teams can proceed safely and legally.

    What is land value tax and how could it help the housing crisis?

    Land value tax (LVT) is a levy on the unimproved value of land itself, separate from any buildings on it. Unlike council tax or stamp duty, it discourages land banking and incentivises development, since holding undeveloped land becomes costly. Advocates at institutions including the London School of Economics argue it could unlock tens of thousands of stalled planning consents and reduce speculative land price inflation.

    Is the rental market crisis as serious as the homeownership crisis in the UK?

    Many economists now argue the rental market crisis is equally acute. Private rents in England rose approximately 9% in the year to March 2025 according to ONS data, with renters in major cities often spending 40% or more of net income on housing costs. The collapse of social housing supply since the 1980s has pushed millions into the private rented sector with limited security of tenure or affordability protection.

  • Quantum Computing Explained: What the Breakthrough Moment Actually Means for Everyday Life

    Quantum Computing Explained: What the Breakthrough Moment Actually Means for Everyday Life

    There is a particular kind of hype that surrounds quantum computing. It arrives in waves, usually attached to a press release from Google, IBM, or a well-funded start-up, and it tends to describe something called a “milestone” in language so breathless it is almost impossible to extract the actual meaning. What has changed? What does it do? And, most importantly, does any of it matter to the person checking their Barclays account on the Tube? The answer, in the long run, is yes. Quite significantly. Here is the quantum computing breakthrough explained, without the theatre.

    Cryogenic quantum computing processor in a research laboratory, illustrating the quantum computing breakthrough explained
    Cryogenic quantum computing processor in a research laboratory, illustrating the quantum computing breakthrough explained

    What Does a Quantum Computer Actually Do Differently?

    A classical computer, the sort running every smartphone, laptop, and data centre on the planet, processes information as bits. A bit is either a zero or a one. Binary. Simple. A quantum computer uses quantum bits, or qubits, which can exist in a state called superposition, essentially being zero and one simultaneously, until they are measured. This is not a metaphor or a shorthand. It is a physical property of particles at the subatomic level, and it allows quantum machines to explore vast numbers of possible solutions to a problem at the same time rather than working through them sequentially.

    Add to that a second property called entanglement, where two qubits can be linked such that the state of one instantly determines the state of the other regardless of distance, and you have the makings of a machine that can tackle certain categories of problem at speeds that would take a classical supercomputer millions of years. The emphasis on certain categories is critical. Quantum computers are not universally faster. They are extraordinarily faster at specific tasks, and those tasks happen to include some of the most consequential in modern life.

    What This Means for Cybersecurity in the UK

    This is where the stakes become genuinely serious. The encryption underpinning almost all secure digital communication, from online banking to NHS patient records to government communications, relies on the mathematical difficulty of factoring enormous numbers. Specifically, it is extraordinarily hard for a classical computer to find the two prime numbers that multiply together to produce a given very large number. RSA encryption, used across the internet, is built on this difficulty.

    A sufficiently powerful quantum computer, running an algorithm called Shor’s algorithm, could break RSA encryption in hours. We are not there yet. Current quantum machines are too error-prone and operate with too few stable qubits to threaten live encryption. But the trajectory is clear, and security professionals have been sounding the alarm for years. The National Cyber Security Centre, which is part of GCHQ, has already published guidance urging organisations to begin migrating towards post-quantum cryptography. The threat is not abstract or distant. Nation-state actors are already harvesting encrypted data today, intending to decrypt it once quantum capability reaches the necessary threshold. This is known in the intelligence community as “harvest now, decrypt later”.

    The quantum computing breakthrough explained in security terms is this: the locks protecting the internet were designed without quantum keys in mind, and the window to replace them is narrowing.

    Cybersecurity analyst working at a London office, representing quantum computing breakthrough explained implications for encryption
    Cybersecurity analyst working at a London office, representing quantum computing breakthrough explained implications for encryption

    Pharmaceuticals and the Drug Discovery Revolution

    Here the implications are considerably more hopeful. Drug discovery is, at its core, a problem of molecular simulation. To design a drug that interacts precisely with a protein in the human body, researchers must model the quantum behaviour of electrons in those molecules. Classical computers are spectacularly bad at this. They approximate and simplify. The result is a drug development pipeline that costs billions of pounds and takes over a decade, with a high failure rate.

    Quantum computers are naturally suited to modelling molecular interactions because they operate on quantum mechanical principles themselves. IBM, in collaboration with several European pharmaceutical partners, has demonstrated that even current noisy intermediate-scale quantum devices can simulate small molecules more accurately than classical methods. Companies such as Cambridge Quantum, now part of Quantinuum and headquartered in the UK, are already working with pharmaceutical firms on drug discovery pipelines that exploit this advantage.

    The practical implication: conditions that have resisted effective treatment, from antibiotic-resistant infections to certain cancers to neurodegenerative diseases, may become tractable problems for quantum-assisted drug design within the next ten to fifteen years. That is not a guarantee, but it is a plausible and well-evidenced trajectory that distinguishes genuine progress from mere hype.

    What Happens to Finance When Quantum Arrives

    The City of London processes extraordinary volumes of financial transactions daily. Optimisation problems, including portfolio management, risk assessment, fraud detection, and derivative pricing, are computationally intensive in ways that suit quantum acceleration rather well. Banks including Barclays and HSBC have been investing in quantum research partnerships for several years, conscious that the institution which first deploys quantum optimisation at scale gains a structural advantage over every competitor still running classical algorithms.

    There is also a darker edge. The same encryption vulnerability that threatens cybersecurity applies to financial systems. SWIFT transfers, card payment networks, and interbank communications all rely on cryptographic standards that quantum computing could eventually compromise. The Bank of England and the FCA are watching this space closely. Financial institutions operating in the UK will face regulatory expectations to demonstrate quantum-readiness in their security architecture, likely before the end of this decade.

    Personal Privacy and What Ordinary People Should Know

    For most people, the quantum computing breakthrough explained at a personal level comes down to one question: should I worry about my passwords and data today? The honest answer is not immediately, but yes, in the medium term. The passwords and two-factor authentication systems in use today are adequate against classical attack. Against a mature quantum adversary, they will not be.

    The reassuring counterpoint is that the technology industry is not waiting passively. The US National Institute of Standards and Technology (NIST) finalised its first post-quantum cryptographic standards in 2024, and UK technology providers are expected to adopt these across critical infrastructure progressively. Apple has already introduced post-quantum protections in iMessage. Signal followed. The migration is slow, uneven, and largely invisible to end users, but it is happening.

    According to the National Cyber Security Centre, organisations should begin their quantum-readiness assessments now rather than waiting for the threat to materialise. That advice applies to businesses of all sizes, not merely large enterprises.

    The Timeline: Grounded Expectations Over Grand Predictions

    The consistent failure of quantum forecasting has been overconfidence about timelines. Predictions of “quantum supremacy within five years” have been circulating since the early 2010s. What has actually happened is slower, messier, and more interesting: genuine scientific progress, significant engineering improvements in qubit stability and error correction, and an emerging commercial ecosystem. The UK government has committed over £2.5 billion to its National Quantum Strategy, recognising that quantum technology, broadly defined, represents a generational strategic and economic opportunity.

    A cryptographically relevant quantum computer, one capable of breaking current encryption at scale, remains arguably ten to fifteen years away. Quantum advantage in drug discovery and financial optimisation is closer, likely within five to eight years for specific applications. The technology will not arrive all at once, like a light being switched on. It will seep into particular sectors, solving particular problems, whilst classical computing continues to handle everything else. That is both the more accurate picture and, in some respects, the more interesting one.

    The quantum computing breakthrough explained honestly is this: not a single moment, but a decade of compound consequences, arriving unevenly, touching cybersecurity first and most urgently, reshaping pharmaceuticals and finance in the medium term, and eventually demanding that every institution, regulator, and citizen reconsider assumptions about digital security that have held since the 1970s. The hype is real and often tiresome. The underlying technology is also real, and the implications are worth understanding now, before the timeline compresses further.

    Frequently Asked Questions

    Has there actually been a quantum computing breakthrough, or is it just marketing?

    There have been several genuine milestones, including Google’s 2019 claim of quantum supremacy and IBM’s progressive scaling of stable qubits. These are real engineering achievements, though none yet threatens practical encryption or delivers commercial quantum advantage at scale. The breakthroughs are incremental and real; the timelines promised by marketing teams are frequently not.

    How soon could quantum computers break my bank's encryption?

    Current estimates from cybersecurity experts suggest a cryptographically relevant quantum computer, capable of breaking RSA encryption used by banks, is roughly ten to fifteen years away. However, the ‘harvest now, decrypt later’ threat means sensitive data transmitted today could be at risk in the future, which is why the NCSC is urging organisations to begin migrating to post-quantum cryptography now.

    What is the UK doing to prepare for quantum threats?

    The UK government has committed over £2.5 billion to its National Quantum Strategy, and the National Cyber Security Centre has published specific guidance for organisations on preparing for post-quantum cryptography. UK universities, including those in Cambridge and Bristol, are among the leading research centres globally for quantum technology.

    Will quantum computing help find cures for diseases?

    Quantum computers are particularly well-suited to simulating molecular behaviour, which is the core challenge in drug discovery. UK-based Quantinuum is already partnering with pharmaceutical companies on this. Realistic timelines suggest meaningful quantum-assisted drug discovery could arrive within the next five to ten years for specific conditions.

    Do I need to do anything now to protect my personal data from quantum threats?

    For most individuals, no immediate action is required. However, using end-to-end encrypted messaging apps such as Signal, which have already adopted post-quantum protections, is a sensible precaution. Staying alert to password hygiene and enabling two-factor authentication remains the most practical personal security measure for now.

The Latest